In short
This article discusses a clinical trial investigating the bioequivalence of a new single-tablet formulation of paracetamol and codeine phosphate hemihydrate compared to a standard two-tablet formulation. The study aims to evaluate the rate and extent of absorption of these medications in healthy volunteers under fasting conditions. Understanding the results of this trial could lead to more convenient dosing options for patients requiring pain relief.
At a glance
- Study Type
- Bioequivalence study
- Medications Compared
- One tablet of Paracetamol 1000 mg/Codeine 30 mg vs. Two tablets of Paracetamol 500 mg/Codeine 30 mg
- Participants
- Healthy male and female volunteers
- Study Design
- Two-period, single-dose administration with washout period
- Primary Outcomes
- Cmax and AUC(0-t) for paracetamol and codeine
- Secondary Outcomes
- AUC(0-∞), Tmax, Terminal half-life, Apparent First Order Terminal Rate Constant, Time Until First Nonzero Concentration, Safety assessments
- Safety Monitoring
- Adverse events, vital signs, physical examinations, laboratory parameters, body weight, ECG
What is Codeine Phosphate Hemihydrate?
Codeine Phosphate Hemihydrate is a medication that belongs to a class of drugs known as opioid analgesics. It is commonly used in combination with other pain relievers, such as paracetamol (also known as acetaminophen), to manage moderate pain. The term "hemihydrate" refers to the chemical structure of the compound, which includes half a molecule of water for each molecule of codeine phosphate.
Uses and Conditions Treated
While the clinical trial data provided doesn't explicitly state the conditions treated by Codeine Phosphate Hemihydrate, it's generally used for: Pain management: Codeine is often combined with paracetamol to treat moderate pain that isn't relieved by other painkillers alone. Cough suppression: Although not mentioned in the trial data, codeine is also known for its cough-suppressing properties. It's important to note that in the clinical trial, the medication was tested on healthy volunteers, which is common practice in bioequivalence studies to assess how the drug behaves in the body without the influence of any medical conditions.
New Formulation and Bioequivalence Study
The clinical trial data describes a study comparing a new formulation of codeine and paracetamol to an existing one: New formulation: One tablet containing 1000 mg of paracetamol and 30 mg of codeine phosphate hemihydrate. Existing formulation (reference product): Two tablets of Co-efferalgan®, each containing 500 mg of paracetamol and 30 mg of codeine phosphate hemihydrate. The purpose of this study was to determine if the new single-tablet formulation is bioequivalent to the existing two-tablet formulation. Bioequivalence means that the two formulations have the same effect and behave similarly in the body.
Administration and Dosage
In the clinical trial: The new formulation was administered as a single tablet of paracetamol 1000 mg/codeine 30 mg. The reference formulation was given as two tablets of paracetamol 500 mg/codeine 30 mg. Both formulations were given as a single dose under fasting conditions (meaning participants hadn't eaten before taking the medication). It's important to note that this dosing was specific to the clinical trial and may not reflect typical patient dosing. Always follow your healthcare provider's instructions for taking any medication.
Pharmacokinetics: How the Body Processes Codeine
The study measured several aspects of how the body processes codeine and paracetamol, known as pharmacokinetics. These include: Cmax: The maximum concentration of the drug in the blood. AUC (Area Under the Curve): A measure of the total exposure to the drug over time. Tmax: The time it takes to reach the maximum concentration. Half-life: The time it takes for the concentration of the drug in the body to be reduced by half. These measurements were taken at various time points from 5 minutes to 36 hours after taking the medication, allowing researchers to understand how quickly the drugs are absorbed, how long they stay in the body, and how they are eliminated.
Safety and Side Effects
While the primary focus of the study was on bioequivalence, safety was also monitored. The researchers looked at: Treatment-Emergent Adverse Events (TEAEs): Any new side effects or worsening of existing conditions that occur after starting the treatment. Vital signs: Including blood pressure (BP) and heart rate (HR). Physical examinations Laboratory parameters Body weight ECG (Electrocardiogram): A test that checks for problems with the electrical activity of your heart. These safety measures were monitored throughout the study period. It's important to remember that all medications can have side effects, and you should always discuss potential risks and benefits with your healthcare provider.